Cencora (COR) has put up a busy Q2 2026, with revenue of about US$78.4b, basic EPS of US$8.44 and net income of US$1,641.3m setting the tone for this earnings season update. Over the past six reported quarters, revenue has moved between roughly US$75.5b and US$86.0b while quarterly EPS has ranged from a loss of US$1.75 to a high of US$8.44. This gives investors a clear view of how the earnings line has tracked alongside a very large top line. Taken together with trailing twelve month EPS of US$13.13 and a net profit margin that is currently higher than a year ago, the latest print highlights a business where profitability is front and center for investors watching how margins hold up on such a large revenue base.

See our full analysis for Cencora.

With the headline numbers on the table, the next step is to see how this earnings profile compares with the widely shared narratives about Cencora’s growth potential, risk profile and long term profitability story.

50.5% earnings growth and 0.8% margin

• Over the last 12 months, Cencora generated about US$328.7b of revenue and US$2.5b of net income, which works out to 50.5% earnings growth and a 0.8% net margin compared with 0.5% a year earlier.
• Consensus narrative points to digital investments and higher margin specialty drugs as key profit drivers, and this margin profile lines up with that view, although:
  • Trailing twelve month EPS of US$13.13 and net income of US$2.5b sit alongside relatively thin margins, so any cost pressure would have an outsized effect on profit.
  • Forecast earnings growth of about 8.8% per year is described as much slower than the recent 50.5% pace, which challenges the most bullish expectations for ongoing acceleration.

P/E of 19.5x vs 22.4x industry

• The stock trades at a P/E of 19.5x versus 20.4x for peers and 22.4x for the wider US healthcare group, while the current share price of US$255.66 sits well below both the US$373.08 analyst consensus target and the US$606.70 DCF fair value.
• Supporters of the bullish narrative see this as a valuation gap, and the latest numbers lean in that direction, yet with some caveats:
  • Revenue of roughly US$328.7b over the last year and forecasts for about 6.6% annual revenue growth suggest a large, slower growing base rather than a high growth story, which may justify part of the discount.
  • Analysts expecting earnings to climb to US$3.6b and EPS of US$20.25 by around 2029 are also assuming a future P/E of 25x, higher than today and above the current industry multiple, so investors need to be comfortable with that rerating assumption.

Bulls who think Cencora’s growth and margin story can support a higher multiple may want to see how that view is built out in detail in the dedicated bull case 🐂 Cencora Bull Case

Debt coverage risk vs cash generation

• One of the key flagged risks is that debt is not well covered by operating cash flow, even though trailing twelve month net income is US$2.5b and analysts expect earnings to reach about US$3.6b over the next few years.
• Critics in the bearish narrative focus on this leverage concern along with margin pressure, and the current figures give that view some support:
  • Net margin at 0.8% leaves limited room for error if pricing pressure from biosimilars, generics, or regulatory changes weighs on profitability, given how much revenue is required to generate each dollar of earnings.
  • Weak operating cash flow coverage of debt means that even moderate shifts in volumes or fees could matter for balance sheet comfort, especially if international operations and consulting remain under pressure.

Anyone cautious about how Cencora’s thin margins and debt coverage could interact over time may find it helpful to walk through the detailed bear case narrative next 🐻 Cencora Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cencora on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With the mix of risks and rewards laid out, how do you feel about Cencora’s story so far, and does it fit your own risk tolerance and return expectations? To weigh the trade off between the concerns and the upside potential using the same data set, take a closer look at the 5 key rewards and 1 important warning sign

Explore Alternatives

Cencora’s thin 0.8% net margin, weak debt coverage by operating cash flow and reliance on a very large revenue base leave little room for error.

If that mix of tight margins and leverage makes you uneasy, compare Cencora with companies that prioritize financial resilience by filtering for the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.